David Broser

Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD.

William Harris Investors, Inc. (WHI) is a privately-owned investment and wealth management firm headquartered in Chicago, Illinois. The firm serves as the family office for the Irving B. Harris family. Founded in 1976 by Irving B. Harris to manage his own family's capital, WHI has expanded its services and today provides a broad range of professional and wealth management services, including financial and estate planning, trust services, cash management, accounting and administrative services, tax preparation, and a variety of philanthropic services to four generations of the Harris family.

Pharmasset, Inc. developed drugs to treat viral infections. It focued in the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. The company was founded in 1998 and was headquartered in Princeton, NJ.

The International Centre for Missing & Exploited Children is an organization that focuses on finding missing children and protecting children from exploitation worldwide. The non-profit company is based in Alexandria, VA and the CEO of the company is Paul Shapiro. The company's work involves powering the search for missing children and implementing measures to safeguard children from harm.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

DuPont Pharmaceuticals Co. researches and develops pharmaceuticals and imaging products to treat diseases. It focuses on pharmaceuticals to treat unmet medical needs in the fight against HIV, cardiovascular disease, central nervous system disorders, cancer and arthritis-related disorders. The company is located in Wilmington, DE.

The American Foundation For AIDS Research, Inc. provides research services. It plays a role in AIDS research, identifying critical gaps in their knowledge of HIV and AIDS. The company was founded in 1985 and is headquartered in New York, NY.

TrioBiotics Pharma AG manufactures pharmaceuticals for the treatment of psychiatric, cancer and infectious diseases. It offers anti-infectives for chronic and infectious disease markets. The company is headquartered in Zurich, Switzerland.

Part of Cocrystal Pharma, Inc., RFS Pharma LLC develops novel medicines for use in the treatment of human viral diseases. The company is based in Tucker, GA. RFS Pharma was acquired by Cocrystal Pharma, Inc. on November 25, 2014. The company was founded by Raymond F. Schinazi.

Part of Novartis AG, Sandoz Corp. develops, produces, and markets medicines.

Global Virus Network conducts research on essential and critical defense against viral diseases. The non-profit company is based in Baltimore, MD. The company was founded by William Walmsley Hall and Robert C. Gallo.

Brace Pharmaceuticals, Inc (Brace Pharmaceuticals) is a venture capital firm founded in 2013. The firm is headquartered in Atlanta.

WHI Special Investments LLC operates as a pooled investment fund. The company is headquartered in Chicago, IL.

ReViral Ltd. specializes in the areas of virology and antiviral therapies. It offers drugs to treat respiratory synctial virus infection. The company was founded by Neil Matthews and Stuart Cockerill in 2011 and is headquartered in Stevenage, the United Kingdom.

Petrichor Healthcare Capital Management LP (Petrichor) is a private equity firm founded in 2016 by Tadd Wessel. The firm headquartered in New York.

ArTara Subsidiary, Inc. engages in the research and development of specialty diseases therapeutics. Its programs focus on the treatment of rare diseases in structural and connective tissues, as well as rare hepatology or gastrointestinal and metabolic disorders. The company was founded by Jesse Shefferman in 2017 and is headquartered in New York, NY.

First In Ventures LLC provides investment services. The company is headquartered in Middletown, DE.

RIGImmune, Inc. is a platform biopharmaceutical company based in Farmington, CT, with subsidiaries in the United Kingdom. The company is developing a novel investigational class of RNA immunotherapies called "SLRs" for the potential pan-viral treatment and prophylaxis of viral respiratory diseases and selected cancers. The lead development candidate at RIGImmune is RIG-101, which specifically modulates RIG-I, a host surveillance pathway that triggers the innate immune system to enhance an intrinsic response to RNA viruses, including influenza, RSV, rhinovirus, and SARS-CoV-2, and tumor DNA. The company was founded in 2020 by Akiko Iwasaki and Anna Marie Pyle, both prominent Yale University professors who currently serve as scientific advisors to the company.

Bolden Therapeutics, Inc. is a biotechnology company that is developing first-in-class therapeutics to treat central nervous system diseases. The company's research facilities are based within Tufts Launchpad Biolabs, a leading incubator for next-generation powerhouse biotech startups located in Providence, RI. The company's scientific co-founders, Dr. Justin Fallon and Dr. Ashley E. Webb, have identified a key molecular pathway to stimulate neural stem cells to promote the birth of new neurons in the adult brain. Bolden is developing antisense oligonucleotides to modulate this genetically-validated target. The company was founded by Justin Fallon, Ashley E. Webb, and Johnny Page. Johnny Page has been the CEO since incorporation.